Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
| ClinicalTrials.gov Identifier |
| NCT05285358 |
| Institution Name |
| City of Hope Comprehensive Cancer Center |
| Institution Address (Street) |
| 1500 East Duarte Road |
| Institution City |
| Duarte |
| Institution State |
| California |
| Institution ZIP Code |
| 91010 |
| Institution Country |
| United States |
| Institution Phone |
| 626-471-9200 |
| Principal Investigator |
| Daneng Li |
| Principal Investigator Phone |
| (626) 471-9200 |
| Principal Investigator Email |
| danli@coh.org |
| Additional Principal Investigators |
| Mustafa Raoof, MD 626-471-9200 mraoof@coh.org |
| Study Coordinator |
| NA |
| Study Coordinator Email |
| danli@coh.org |
| Study Overview |
| This phase I trial studies the side effects and effect of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel in combination with gemcitabine and cisplatin in treating patients with biliary tract cancer that has spread to the peritoneum (peritoneal metastases). |
| Enrollment Information |
| 12 |
| Study Start Date |
| 20220711 |
| Study End Date |
| 20240307 |
| Financial Assistance Available |
| No |